newsfilter
← Latest News
PR Newswire·

Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study

On track to complete data compilation and analyses, with top-line data expected to be announced in December '22 LOS GATOS, Calif., Oct. 4, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) announced today that patient enrollment is clos